Skip to main content Accessibility help
×
Home

Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers

  • M. BORELLA-VENTURINI (a1), C. FRASSON (a1), F. PALUAN (a1), D. DE NUZZO (a1), G. DI MASI (a1), M. GIRALDO (a1), F. CHIARA (a1) and A. TREVISAN (a1)...

Summary

The aim of the present research is to verify the immune status against tetanus in students and workers exposed to risk and to ascertain whether a decennial booster is necessary. Antibodies against tetanus were measured in 1433 workers and students of Padua University (Italy). The enrolment criterion was the ability to provide a booklet of vaccinations released by a public health office. The influence of age, gender, the number of vaccine doses, and the interval since the last dose was determined. Ten years after the last dose, the majority of subjects (95·0%) displayed an antibody titre above the protective level (⩾0·10 IU/ml), and half of these (49·1%) had a long-term protective level (⩾1·0 IU/ml). According to our data, titre depends on both the number of vaccine doses and the interval since the last dose (P < 0·0001). Five vaccine doses and an interval of at least 10 years since the last dose are predictive of a long-term protective titre in absence of a booster (1·97 IU/ml). These data suggest that when primary series are completed, a decennial booster is unnecessary for up to 20 years. Furthermore, we recommend measuring the antibody level before a new booster is given to prevent problems related to over-immunisation.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Prof. A. Trevisan, Department of Cardiologic, Thoracic and Vascular Sciences, Unit of Preventive Medicine and Risk Assessment, University of Padova, Via Giustiniani 2, I-35128 Padova, Italy. (Email: andrea.trevisan@unipd.it)

References

Hide All
1. Centers for Disease Control and Prevention. Tetanus among injecting-drug users-California, 1997. Morbidity and Mortality Weekly Report 1998; 47(8): 149151.
2. Bennett, J, et al. Bundling, a newly identified risk factor for neonatal tetanus: implications for global control. International Journal of Epidemiology 1996; 25: 879884.
3. Filia, A, et al. Tetanus in Italy 2001–2010: a continuing threat in older adults. Vaccine 2014; 32: 639644.
4. Yildirim, RC, et al. Tetanus IgG antibody levels in children aged 12 to 47 months in Turkey. American Journal of Infection Control 2001; 29: 120124.
5. Edsall, G, et al. Excessive use of tetanus toxoid boosters. The Journal of the American Medical Association 1967; 202: 111113.
6. National Advisory Committee on Immunization (NACI). Interval between administration of vaccines against diphtheria, tetanus, and pertussis. Canada Communicable Disease Report 2005; 31(ACS-9): 1722.
7. European Centre for Disease Prevention and Control. Annual epidemiological report 2012. Reporting on 2010 surveillance data and 2011epidemic intelligence data. Stockholm: ECDC; 2013. (http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf).
8. Chatchatee, P, et al. Seroprevalence of tetanus antibody in the Thai population: a national survey. Asian Pacific Journal of Allergy and Immunology 2007; 25: 219223.
9. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report 2006; 55(RR-03): 134.
10. World Health Organization. Tetanus vaccine: WHO position paper. The Weekly Epidemiological Record 2006; 81: 198208.
11. Coulibaly, N, De Serres, G. Couverture vaccinale antitétanique des adultes au Canada-année 2002. Canadian Journal of Public Health 2004; 95: 456459.
12. Maple, PAC, et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2001; 19: 167173.
13. Schatz, D, et al. Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation. Clinical and Diagnostic Laboratory Immunology 1998; 5: 894896.
14. Peel, MM, et al. Relationship between lymphocyte response to tetanus toxoid and age of lymphocyte donor. The Journal of Hygiene 1978; 80: 259265.
15. Bayas, JM, et al. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary? Epidemiology and Infection 2001; 127: 451460.
16. Hüllstrung, HD, et al. Tetanus immunisation in geriatric patients with accidental wounds: how much is needed? Swiss Medical Weekly 2003; 133: 227232.
17. Hammarlund, E, et al. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis. Clinical Infectious Diseases 2016; 62: 11111118.
18. Gottlieb, S, et al. (1964) Long-term immunity to tetanus—a statistical evaluation and its clinical implications. American Journal of Public Health Nation Health 1964; 54: 961971.
19. Chithra, A, et al. Role of rapid tetanus antibody test in accident and emergency department. Journal of Maxillofacial and Oral Surgery 2015; 14: 784788.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed